Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,484 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched Placebo (Capsules) Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Los Angeles, California • Santa Barbara, California • Torrance, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

NCT00407745
View directory record Official record
Conditions
Neuralgia, Spinal Cord Injuries
Interventions
placebo, pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
22
States / cities
Phoenix, Arizona • Fresno, California • Napa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

NCT06619847
View directory record Official record
Conditions
Acute Pain
Interventions
VX-993, HB/APAP, Placebo (matched to VX-993), Placebo (matched to HB/APAP)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

NCT02293148
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 3, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

NCT01416948
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Methylphenidate Hydrochloride 20 mg, Placebo Capsule, Galantamine 12 mg
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
San Diego, California • Boston, Massachusetts • Manchester, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

NCT00622284
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI 1356 5mg, Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, BI 1356, Glimepiride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
23
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

MW151-101: First-in-human Study of MW151

NCT04120233
View directory record Official record
Conditions
Drug Toxicity
Interventions
Placebo, MW151, 10mg, MW151, 20mg, MW151, 40mg, MW151, 80mg, MW151, 160mg
Drug
Lead sponsor
Linda Van Eldik
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 3, 2026, 5:31 AM EDT
Not yet recruiting Phase 4 Interventional

Impact of Probiotics on Gut Microbiome During Antibiotic Prophylaxis in Elective Orthopedic Surgery

NCT06791993
View directory record Official record
Conditions
Dysbiosis, Gut -microbiota, Microbiome Analysis, Probiotic, Antibiotic Prophylaxis
Interventions
Placebo Capsule, Probiotic with Human Milk Oligosaccharides (HMO)
Drug · Dietary Supplement
Lead sponsor
Acibadem Maslak Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 3, 2026, 5:31 AM EDT
Recruiting Phase 3 Interventional

BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT07755904
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic Obstructive
Interventions
BHB-1893, Metoprolol
Drug
Lead sponsor
Braveheart Bio, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Manhasset, New York • Rock Hill, South Carolina • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

American Ginseng Treatment for Multiple Sclerosis Related Fatigue

NCT00754832
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
American ginseng extract HT-1001, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

NCT02720263
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, Matching Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01179516
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
61
States / cities
Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 3, 2026, 5:31 AM EDT
Recruiting Phase 2 Interventional

Bempedoic Acid Therapy for Polycystic Kidney Disease

NCT07282821
View directory record Official record
Conditions
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Interventions
Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s)
Drug
Lead sponsor
Kenneth Hallows
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study

NCT01729598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)

NCT02840799
View directory record Official record
Conditions
Heart Failure
Interventions
Potassium Nitrate (KNO3), Potassium Chloride (KCl)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Evanston, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

NCT00545532
View directory record Official record
Conditions
Influenza, Human
Interventions
oseltamivir, placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
60
States / cities
Birmingham, Alabama • Beverly Hills, California • Burbank, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

NCT04026113
View directory record Official record
Conditions
Functional Constipation, Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
79
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

NCT01572727
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, BKM120 matching placebo, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study of PF-04991532 in Healthy Subjects

NCT01102673
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Study of NXN 188 for the Treatment of Migraine With Aura

NCT00920686
View directory record Official record
Conditions
Migraine With Aura
Interventions
NXN-188, placebo, sumatriptan succinate
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Newport Beach, California • Oceanside, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

NCT02270983
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
77
States / cities
Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine for Adolescent Alcohol Use Disorder

NCT03707951
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
N-acetylcysteine, Placebo oral capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years to 25 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

NCT01809327
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 3, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

NCT00986531
View directory record Official record
Conditions
Schizophrenia
Interventions
AZD8529, Placebo to match AZD8529
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Oct 3, 2026, 5:31 AM EDT